GlassScriptPhysician profile
Karim Welaya
NPI 1841600491
$861.22
in general payments reported to CMS, 2019-2025
17 companies · $359 in 2025
The $359 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.63 · 2022: $110 · 2023: $79.99 · 2024: $249 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $688.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $327.10 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Novartis Pharmaceuticals Corporation | $78.63 | 2024 | |
| Daiichi Sankyo INC. | $73.37 | 2024-2025 | Enhertu, Datroway |
| Pfizer INC. | $68.27 | 2023-2025 | |
| Abbvie INC. | $63.83 | 2023-2025 | Venclexta |
| Emd Serono, INC. | $58.90 | 2025 | |
| Eisai INC. | $37.84 | 2021-2022 | |
| Glaxosmithkline, LLC. | $27.82 | 2025 | Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $22.77 | 2022 | |
| Gilead Sciences, INC. | $20.62 | 2022 | |
| Dova Pharmaceuticals | $14.99 | 2021 | |
| Tersera Therapeutics LLC | $14.39 | 2021 | |
| Springworks Therapeutics, INC. | $14.31 | 2024 | Ogsiveo |
| E.R. Squibb & Sons, L.L.C. | $14.01 | 2025 | Opdivo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.30 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $11.07 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karim Welaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.